chartexchange

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

GlobeNewswire Inc. | Sep 23, 2026 9:17 AM EDT

THIO-104 advances toward key 2027 interim survival analysis

Read original article